Cogent Biosciences, Inc.COGTNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +27.36% | +19.52% | +15.34% | +3.90% | -38.80% |
| Weighted Average Shares Diluted Growth | +27.36% | +19.52% | +15.34% | +3.90% | -38.80% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +4.61% | -40.39% | -36.08% | +10.92% | +185.94% |
| Book Value per Share Growth | -21.95% | -56.61% | -63.99% | -7.49% | +305.74% |
| Debt Growth | -7.35% | -7.73% | +233.58% | +239.67% | +1349.32% |
| R&D Expense Growth | +27.35% | +19.59% | +12.44% | +8.45% | +19.88% |
| SG&A Expenses Growth | +22.93% | +22.73% | +32.56% | +21.75% | +104.76% |